Find clinical trials for Acute Myeloid Leukemia (AML) in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Paris, Île-de-France, FRA:
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Paris, France and 26 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Paris, Île-de-France Region, France and 87 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid...
Phase 1, Phase 2
Paris, France and 8 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Bobigny, Ile-de-France, France and 160 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Paris, France and 55 other locations
Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the ...
Phase 3
Paris, France and 52 other locations
when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progr...
Phase 2
Paris, France and 40 other locations
inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refr...
Phase 1, Phase 2
Paris, Île-de-France, France and 34 other locations
with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...
Phase 1, Phase 2
Paris Cedex 10, France and 48 other locations
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...
Phase 1
Saint-Cloud, France and 23 other locations
Clinical trials
Research sites
Resources
Legal